767 related articles for article (PubMed ID: 33539819)
1. SARS-CoV-2 entry inhibitors by dual targeting TMPRSS2 and ACE2: An in silico drug repurposing study.
Baby K; Maity S; Mehta CH; Suresh A; Nayak UY; Nayak Y
Eur J Pharmacol; 2021 Apr; 896():173922. PubMed ID: 33539819
[TBL] [Abstract][Full Text] [Related]
2. Target-Centered Drug Repurposing Predictions of Human Angiotensin-Converting Enzyme 2 (ACE2) and Transmembrane Protease Serine Subtype 2 (TMPRSS2) Interacting Approved Drugs for Coronavirus Disease 2019 (COVID-19) Treatment through a Drug-Target Interaction Deep Learning Model.
Choi Y; Shin B; Kang K; Park S; Beck BR
Viruses; 2020 Nov; 12(11):. PubMed ID: 33218024
[TBL] [Abstract][Full Text] [Related]
3. Understanding the binding mechanism for potential inhibition of SARS-CoV-2 Mpro and exploring the modes of ACE2 inhibition by hydroxychloroquine.
Choudhury M; Dhanabalan AK; Goswami N
J Cell Biochem; 2022 Feb; 123(2):347-358. PubMed ID: 34741481
[TBL] [Abstract][Full Text] [Related]
4. Molecular screening of glycyrrhizin-based inhibitors against ACE2 host receptor of SARS-CoV-2.
Ahmad S; Waheed Y; Abro A; Abbasi SW; Ismail S
J Mol Model; 2021 Jun; 27(7):206. PubMed ID: 34169390
[TBL] [Abstract][Full Text] [Related]
5. Contributions of human ACE2 and TMPRSS2 in determining host-pathogen interaction of COVID-19.
Senapati S; Banerjee P; Bhagavatula S; Kushwaha PP; Kumar S
J Genet; 2021; 100(1):. PubMed ID: 33707363
[TBL] [Abstract][Full Text] [Related]
6. Simultaneous Inhibition of SARS-CoV-2 Entry Pathways by Cyclosporine.
Prasad K; Ahamad S; Kanipakam H; Gupta D; Kumar V
ACS Chem Neurosci; 2021 Mar; 12(5):930-944. PubMed ID: 33606519
[TBL] [Abstract][Full Text] [Related]
7. Different compounds against Angiotensin-Converting Enzyme 2 (ACE2) receptor potentially containing the infectivity of SARS-CoV-2: an in silico study.
Shahbazi B; Mafakher L; Teimoori-Toolabi L
J Mol Model; 2022 Mar; 28(4):82. PubMed ID: 35249180
[TBL] [Abstract][Full Text] [Related]
8. Repositioning of histamine H
Ge S; Wang X; Hou Y; Lv Y; Wang C; He H
Eur J Pharmacol; 2021 Apr; 896():173897. PubMed ID: 33497607
[TBL] [Abstract][Full Text] [Related]
9. Can Host Cell Proteins Like ACE2, ADAM17, TMPRSS2, Androgen Receptor be the Efficient Targets in SARS-CoV-2 Infection?
Gupta VK; Murthy MK; Patil S
Curr Drug Targets; 2021; 22(10):1149-1157. PubMed ID: 33243116
[TBL] [Abstract][Full Text] [Related]
10. Screened antipsychotic drugs inhibit SARS-CoV-2 binding with ACE2 in vitro.
Lu J; Hou Y; Ge S; Wang X; Wang J; Hu T; Lv Y; He H; Wang C
Life Sci; 2021 Feb; 266():118889. PubMed ID: 33310043
[TBL] [Abstract][Full Text] [Related]
11. Strong Binding of Leupeptin with TMPRSS2 Protease May Be an Alternative to Camostat and Nafamostat for SARS-CoV-2 Repurposed Drug: Evaluation from Molecular Docking and Molecular Dynamics Simulations.
Ramakrishnan J; Kandasamy S; Iruthayaraj A; Magudeeswaran S; Chinnasamy K; Poomani K
Appl Biochem Biotechnol; 2021 Jun; 193(6):1909-1923. PubMed ID: 33512650
[TBL] [Abstract][Full Text] [Related]
12. Prevention of SARS-CoV-2 cell entry: insight from
Gyebi GA; Adegunloye AP; Ibrahim IM; Ogunyemi OM; Afolabi SO; Ogunro OB
J Biomol Struct Dyn; 2022 Mar; 40(5):2121-2145. PubMed ID: 33089728
[TBL] [Abstract][Full Text] [Related]
13. The neutralization effect of montelukast on SARS-CoV-2 is shown by multiscale in silico simulations and combined in vitro studies.
Durdagi S; Avsar T; Orhan MD; Serhatli M; Balcioglu BK; Ozturk HU; Kayabolen A; Cetin Y; Aydinlik S; Bagci-Onder T; Tekin S; Demirci H; Guzel M; Akdemir A; Calis S; Oktay L; Tolu I; Butun YE; Erdemoglu E; Olkan A; Tokay N; Işık Ş; Ozcan A; Acar E; Buyukkilic S; Yumak Y
Mol Ther; 2022 Feb; 30(2):963-974. PubMed ID: 34678509
[TBL] [Abstract][Full Text] [Related]
14. Withanone from
Balkrishna A; Pokhrel S; Singh H; Joshi M; Mulay VP; Haldar S; Varshney A
Drug Des Devel Ther; 2021; 15():1111-1133. PubMed ID: 33737804
[TBL] [Abstract][Full Text] [Related]
15. Targeting the viral-entry facilitators of SARS-CoV-2 as a therapeutic strategy in COVID-19.
Muralidar S; Gopal G; Visaga Ambi S
J Med Virol; 2021 Sep; 93(9):5260-5276. PubMed ID: 33851732
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the dual effects of antiviral drugs on SARS-CoV-2 receptors and the ACE2 receptor using structure-based virtual screening and molecular dynamics simulation.
Jahantigh HR; Ahmadi N; Shahbazi B; Lovreglio P; Habibi M; Stufano A; Gouklani H; Ahmadi K
J Biomol Struct Dyn; 2023; 41(13):6051-6073. PubMed ID: 35876061
[TBL] [Abstract][Full Text] [Related]
17. The Repurposed ACE2 Inhibitors: SARS-CoV-2 Entry Blockers of Covid-19.
Ahmad I; Pawara R; Surana S; Patel H
Top Curr Chem (Cham); 2021 Oct; 379(6):40. PubMed ID: 34623536
[TBL] [Abstract][Full Text] [Related]
18. Multidisciplinary Approaches Identify Compounds that Bind to Human ACE2 or SARS-CoV-2 Spike Protein as Candidates to Block SARS-CoV-2-ACE2 Receptor Interactions.
Day CJ; Bailly B; Guillon P; Dirr L; Jen FE; Spillings BL; Mak J; von Itzstein M; Haselhorst T; Jennings MP
mBio; 2021 Mar; 12(2):. PubMed ID: 33785634
[TBL] [Abstract][Full Text] [Related]
19. Targeting SARS-CoV-2 Main Protease: A Computational Drug Repurposing Study.
Baby K; Maity S; Mehta CH; Suresh A; Nayak UY; Nayak Y
Arch Med Res; 2021 Jan; 52(1):38-47. PubMed ID: 32962867
[TBL] [Abstract][Full Text] [Related]
20. The TMPRSS2 Inhibitor Nafamostat Reduces SARS-CoV-2 Pulmonary Infection in Mouse Models of COVID-19.
Li K; Meyerholz DK; Bartlett JA; McCray PB
mBio; 2021 Aug; 12(4):e0097021. PubMed ID: 34340553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
